Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
AssigneeThe Trustees of the University of Pennsylvania
InventorsDaniel J. Powell, Jr., Nathalie Scholler
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions and methods for treating diseases, disorders or conditions associated with dysregulated expression of mesothelin. In one embodiment, the invention relates to a fully human chimeric antigen receptor (CAR) wherein the CAR is able to target mesothelin.
Claims13
An isolated nucleic acid sequence encoding a chimeric antigen receptor (CAR), wherein the isolated nucleic acid sequence encodes an amino acid sequence selected from the group consisting of SEQ ID NO:
- 3, SEQ ID NO:
- 5, and SEQ ID NO:
- 7.
An isolated chimeric antigen receptor (CAR) comprising an amino acid sequence selected from the group consisting of SEQ ID NO:
- 3, SEQ ID NO:
- 5, and SEQ ID NO:
- 7.
A genetically modified cell comprising an isolated nucleic acid sequence encoding a chimeric antigen receptor (CAR), wherein the isolated nucleic acid sequence encodes an amino acid sequence selected from the group consisting of SEQ ID NO:
- 3, SEQ ID NO:
- 5, and SEQ ID NO:
- 7.
A method of providing an anti-tumor immunity in a mammal, the method comprising administering to the mammal an effective amount of a genetically modified cell comprising an isolated nucleic acid sequence encoding a chimeric antigen receptor (CAR), wherein the isolated nucleic acid sequence encodes an amino acid sequence selected from the group consisting of SEQ ID NO:
- 3, SEQ ID NO:
- 5, and SEQ ID NO:
- 7.
A method of treating a mammal having a disease, disorder or condition associated with dysregulated expression of mesothelin, the method comprising administering to the mammal an effective amount of a genetically modified cell comprising an isolated nucleic acid sequence encoding a chimeric antigen receptor (CAR), wherein the isolated nucleic acid sequence encodes an amino acid sequence selected from the group consisting of SEQ ID NO:
- 3, SEQ ID NO:
- 5, and SEQ ID NO:
- 7.
Dependencies are inferred from the claim text.